Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benecta is a dietary supplement developed by the Icelandic biotechnology company Genís. It is composed of short-chain chitosan (chito-oligosaccharides) derived from North Atlantic shrimp shells using a proprietary enzymatic process. Unlike standard long-chain chitosan, the short-chain version used in Benecta is highly bioactive and soluble. The product is primarily marketed to support joint health, improve physical mobility, and reduce age-related fatigue and stiffness. Clinical research conducted by Genís has suggested that Benecta may help maintain physical performance and quality of life in older populations. Its mechanism of action is believed to involve anti-inflammatory and antioxidant effects, although specific molecular targets are not well-defined in standard pharmaceutical terms. It is administered orally, typically in capsule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Benecta.